Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics, ChemNavigator Enter Drug-Discovery Pact

NEW YORK, Sept. 5 – Structural Bioinformatics and ChemNavigator have agreed to combine their technologies in order to identify novel drug candidates, SBI announced on Wednesday.

According to the terms of the agreement, SBI and its customers will have access to ChemNavigator’s iResearch System, a database of chemical structures for 2 million drug-like compounds. This information can then be screened against SBI’s own drug-target database of three-dimensional protein structures.

Although financial details were not disclosed, the companies said in a statement that they would share any revenues generated from the combined use of their technologies.

“Screening our compound library against [SBI’s] active sites will result in the quick identification of drug candidates that can be moved into lead optimization programs in months rather than years,” ChemNavigator CEO Scott Hutton said in the statement.

The companies, both based in San Diego, said they initially plan to apply their joint technologies to investigating clinical targets for certain cancers and diabetes.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.